# Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Source: https://onco.cc/trials/nct05455619/  
OnCo record `nct05455619` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Evexomostat in advanced solid tumours, run by SynDevRx, Inc., now recruiting.

## Summary

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer is a phase 1/2 interventional study registered as NCT05455619 by SynDevRx, Inc., with 52 participants planned, started 2022-08-26 and due to reach its primary completion in 2026-12. Interventions recorded: Evexomostat.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05455619
- Phase: 1/2
- Setting: Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)
- Sponsor: SynDevRx, Inc.
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT05455619: https://clinicaltrials.gov/study/NCT05455619

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Evexomostat](https://onco.cc/drugs/evexomostat/)

---
JSON: https://onco.cc/api/v1/entities/nct05455619.json